ABSTRACT
Purpose
To investigate the single-dose effect of intravitreal dexamethasone (DEX) implant for patients with post-vitrectomy macular edema (ME) under silicone oil (SO) tamponade.
Methods
Twelve eyes diagnosed with ME after undergoing pars plana vitrectomy with SO injections were retrospectively reviewed. Each eye received a single intravitreal DEX implant (0.7-mg, Ozurdex; Allergan Inc) injection as treatment for recalcitrant ME. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were recorded.
Results
Compared with baseline (1.24 ± 0.34), the mean LogMAR BCVA improved at 1 (1.14 ± 0.27), 3 (1.13 ± 0.22), and 6 (1.22 ± 0.30) months without statistical significance. Maximal CMT resolution was observed at 1 month after intravitreal injection. The CMT value improved significantly at 1 (P = .008), 3 (P = .006), and 6 (P = .009) months. IOP did not show significant elevation during follow-up. No serious adverse events were observed.
Conclusion
Single-dose treatment of DEX implant may have benefit for recalcitrant post-vitrectomy ME under SO tamponade.
Author contributions
C.-R.H. and C.-M.Y: substantial contributions to the conception or design of the work.
C.-R.H. and Y.-T.H.: the acquisition, analysis, or interpretation of data for the work.
C.-P.L.: Drafting the work or revising it critically for important intellectual content. C.-M.Y and C.-P.L.: final approval of the version to be published.
C.-R.H. Y.-T.H., C.-M.Y., and C.-P.L.: agreement to be accountable for all aspects of the work.
Declaration of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
Statement of ethics
This study was approved by the Ethics Committee and Institutional Review Board of the National Taiwan University Hospital and adhered to the Declaration of Helsinki. Informed consent was waived due to the retrospective nature of this study and no identifiable details were present.